Long-term experience with tertatolol in hypertension

Area of Science:

• Cardiology
• Pharmacology
• Hypertension Management

Background:

• Placebo-resistant hypertension (HT) poses a significant challenge in long-term patient management.
• Beta-blocking agents are a cornerstone of antihypertensive therapy, but novel agents require thorough evaluation.
• Assessing the efficacy and tolerability of new antihypertensive drugs is crucial for clinical practice.

Purpose of the Study:

• To evaluate the long-term (12-month) antihypertensive activity of tertatolol (5 mg once daily).
• To assess the acceptability and treatment adaptation of tertatolol in patients with stable, placebo-resistant hypertension.
• To determine the percentage of patients achieving blood pressure (BP) normalization under different therapeutic regimens.

Main Methods:

• An open-label, 12-month study involving 110 outpatients with stable hypertension.
• Patients received tertatolol (T) 5 mg once daily, with treatment adjusted by adding a diuretic (D) and/or vasodilator (V) as needed.
• Blood pressure (BP) was monitored throughout the study to assess treatment efficacy.

Main Results:

• At 12 months, 93.6% of patients achieved controlled blood pressure (diastolic BP < 95 mm Hg).
• Monotherapy with tertatolol controlled BP in 72.7% of patients; 16.4% required dual therapy (T+D), and 4.5% needed triple therapy (T+D+V).
• Significant reductions in systolic BP (26.4 mm Hg) and diastolic BP (19.9 mm Hg) were observed (p<0.01).

Conclusions:

• Long-term administration of tertatolol (5 mg once daily) is effective and well-tolerated for managing hypertension.
• Treatment adaptation with diuretics and vasodilators allows for sustained BP control in a high percentage of patients.
• Tertatolol demonstrates early and sustained antihypertensive effects, with comparable efficacy across different age groups and baseline BP levels.